Zobrazeno 1 - 10
of 144
pro vyhledávání: '"Luis Isola"'
Autor:
Madhu Mazumdar, Jung-Yi Joyce Lin, Wei Zhang, Lihua Li, Mark Liu, Kavita Dharmarajan, Mark Sanderson, Luis Isola, Liangyuan Hu
Publikováno v:
BMC Health Services Research, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background The Oncology Care Model (OCM) was developed as a payment model to encourage participating practices to provide better-quality care for cancer patients at a lower cost. The risk-adjustment model used in OCM is a Gamma generalized l
Externí odkaz:
https://doaj.org/article/059758542676435791e09f21c37e7e36
Autor:
Alla Keyzner, Jacques Azzi, Rita Jakubowski, Yelena Sinitsyn, Sharon Tindle, Svitlana Shpontak, Deukwoo Kwon, Luis Isola, Camelia Iancu-Rubin
Publikováno v:
Transplantation Proceedings.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfa41357d683fb5acbf3cabb4eeda474
https://doi.org/10.1016/j.transproceed.2023.03.070
https://doi.org/10.1016/j.transproceed.2023.03.070
Autor:
Kouros Owzar, Ravi Vij, Don M. Benson, Thomas C. Shea, Margarida Silverman, Philip L. McCarthy, Thomas Martin, Vera J. Suman, Kenneth C. Anderson, Paul G. Richardson, Luis Isola, Charles A. Linker, Katelyn Santo, Sarah A. Holstein, Bruce D. Cheson
Publikováno v:
Biol Blood Marrow Transplant
CALGB (Alliance) 100001 was a phase II study evaluating autologous stem cell transplant (ASCT) followed by nonmyeloablative allogeneic stem cell transplant (alloSCT) in patients with multiple myeloma who had received no more than 18 months of prior t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45d00b979dec1d612ff1ca6083c95616
https://doi.org/10.1016/j.bbmt.2020.03.028
https://doi.org/10.1016/j.bbmt.2020.03.028
Autor:
Michael Byrne, Jane L. Liesveld, Richard F. Olsson, Sagar S. Patel, Hongtao Liu, Eric Wong, Brenda M. Sandmaier, Bipin N. Savani, Hannah Choe, Partow Kebriaei, Gulrayz Ahmed, Tania Jain, Moussab Damlaj, Rebecca L. Olin, Mehdi Hamadani, Uday R. Popat, Neil Palmisiano, Rajneesh Nath, Mei-Jie Zhang, Mark R. Litzow, Attaphol Pawarode, Mark P. Hertzberg, Taiga Nishihori, Arnon Nagler, Jean A. Yared, Mitchell S. Cairo, Ioannis Politikos, Michael R. Grunwald, Hisham Abdel-Azim, Usama Gergis, David A. Rizzieri, Baldeep Wirk, Ashish Bajel, Rammurti T. Kamble, Hemant S. Murthy, Jean-Yves Cahn, Corey Cutler, Mahmoud Aljurf, A. Samer Al-Homsi, Geoffrey L. Uy, Miguel-Angel Perales, Muhammad Waqas Khan, Miguel Angel Diaz, Minocher Battiwalla, Mohamed A. Kharfan-Dabaja, Nosha Farhadfar, Natasha Kekre, Vaibhav Agrawal, Hillard M. Lazarus, Jan Cerny, Rodrigo Martino, Nandita Khera, Youjin Wang, Asmita Mishra, Nasheed Hossain, Luis Isola, Leo F. Verdonck, Nirav N. Shah, Vijaya Raj Bhatt, Zachariah DeFilipp, Daniel J. Weisdorf, Vikram Mathews, Edward A. Copelan, Aaron T. Gerds, C. Esar O. Freytes, David Valc A. Arcel, Shahrukh K. Hashmi, Mrinal M. Patnaik, Sunita Nathan, Sachiko Seo, Marcos de Lima, Qaiser Bashir, David I. Marks, Zheng Zhou, Yoshihiro Inamoto, Ryotaro Nakamura, Hai-Lin Wang, Edmund K. Waller, James M. Foran, Gerhard C. Hildebrandt, Amer Assal, Zartash Gul, Hassan B. Alkhateeb, Ulrike Bacher, Wael Saber
Publikováno v:
Blood Advances
There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206e8ff6ed3071549ebdf616172fcb8c
https://doi.org/10.1182/bloodadvances.2019001266
https://doi.org/10.1182/bloodadvances.2019001266
Publikováno v:
Mount Sinai Expert Guides
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d516c05ce47351d82e91eb8d8d421a4
https://doi.org/10.1002/9781119189596.ch34
https://doi.org/10.1002/9781119189596.ch34
Autor:
William H. Smith, Kavita V. Dharmarajan, Anish B. Parikh, Ronald D. Ennis, Mark Liu, Luis Isola, Mark Sanderson
Publikováno v:
Journal of Oncology Practice. 15:e187-e194
PURPOSE: If identifiable, potentially avoidable hospitalizations (PAHs) can serve as an important target for cost containment efforts in oncology. METHODS: PAHs among a cohort of Medicare patients with prostate cancer were identified using a two-stag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d06a54139b3617e63c871ed39713ba85
https://doi.org/10.1200/jop.18.00560
https://doi.org/10.1200/jop.18.00560
Autor:
Haley Hines Theroux, Luis Isola, Alyssa Dahl, Mark Liu, Theresa Dreyer, Alaysia Williams, Keith Horvath
Publikováno v:
JCO oncology practice. 16(10)
PURPOSE: As expenditures for cancer care continue to grow substantially, value-based payment models are being tested to control costs. The Oncology Care Model (OCM) is the largest value-based payment program in oncology. The primary objective of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c20d421fdc39ad248213de565d98f817
https://pubmed.ncbi.nlm.nih.gov/32459566
https://pubmed.ncbi.nlm.nih.gov/32459566
Autor:
Lihua Li, William H. Smith, Luis Isola, Madhu Mazumdar, Mark Sanderson, Kavita V. Dharmarajan, Anish B. Parikh, Mark Liu
Publikováno v:
J Cancer Policy
Purpose/Objectives We sought to estimate the expected cost savings generated if a set of potentially avoidable hospitalizations (PAHs) among oncology care model (OCM) patients with prostate cancer were shifted to an acute care model in the outpatient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d11fdd5d5dcaf59b77236632f9323e06
https://europepmc.org/articles/PMC7189771/
https://europepmc.org/articles/PMC7189771/
Autor:
Luis Isola, Kendra Yum, Sweta U Patel, Sara Kim, Eileen Scigliano, Doyun Park, Rita Jakubowski
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:1762-1766
Graft-versus-host disease has been reported to occur rarely in syngeneic hematopoietic stem cell transplant recipients. Clinical and histological changes consistent with graft-versus-host disease have been reported to occur in this patient population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd1ac1c75a6d16450946e7dfee3db44c
https://doi.org/10.1177/1078155218805541
https://doi.org/10.1177/1078155218805541
Autor:
Koen van Besien, David D. Hurd, Kouros Owzar, Vera Hars, Thomas Martin, Edward A. Stadtmauer, Marcia Wilson, Charles A. Linker, Asad Bashey, Molly Boyd, Sarah A. Holstein, Ravi Vij, Teresa Gentile, Heather Landau, Mary M. Horowitz, Natalie S. Callander, Luis Isola, Philip L. McCarthy, Robert L. Schlossman, Parameswaran Hari, Scott E. Smith, Thomas C. Shea, Hani Hassoun, Jan S. Moreb, Daniel J. Weisdorf, Paul G. Richardson, Steven M. Devine, Kenneth C. Anderson, Marcelo C. Pasquini, Richard T. Maziarz, Craig C. Hofmeister, Muzaffar H. Qazilbash, Chelsea Schultz, Cesar Rodriguez, Brian McClune, Sin-Ho Jung, Chen Jiang, Sergio Giralt
Publikováno v:
The Lancet. Haematology
In the CALGB (Alliance) 100104 study, lenalidomide versus placebo after autologous stem-cell transplantation (ASCT) was investigated for patients with newly diagnosed myeloma. That study showed improved time to progression and overall survival and an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5885770bf20d691c1eaaba4dba197a56
http://europepmc.org/articles/PMC5718627
http://europepmc.org/articles/PMC5718627